One of the main targets of antineoplastic therapy in RCC patients is the mTOR serine/threonine kinase, which forms the catalytic subunit of the complex molecular mTORC1 and is involved in numerous processes responsible for tumor progression. Here, MTOR is linked to renal cell carcinoma.